CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced preliminary results from a Phase 1 clinical study evaluating its oral, triple VEGF receptor inhibitor tivozanib in combination with the mTOR inhibitor temsirolimus (Torisel®), a rapamycin pro-drug, in patients with advanced kidney cancer. Torisel is approved in the United States and European Union for the treatment of advanced kidney cancer. Preliminary results of this ongoing study show tumor shrinkage in 12 out of 16 patients evaluated, and two partial responses as assessed by RECIST criteria; the combination was well-tolerated with no dose limiting toxicities (DLT). These data were presented today at the International Conference, “Molecular Targets and Cancer Therapeutics,” hosted by the American Association for Cancer Research (AACR), National Cancer Institute (NCI), and European Organization for Research and Treatment of Cancer (EORTC) in Boston, Mass.
